Ruthie Davi, vice president of statistics and regulatory innovation at Medidata, highlights the value of technology in rare ...

Q4 2025 Management View Peter Greenleaf, President, CEO & Director, opened the call announcing "strong LUPKYNIS sales in 2025, growing at a rate of 25% year-over-year" and provided 2026 sales ...

Astellas Pharma and AstraZeneca are joining Bristol Myers Squibb by deploying Evinova’s artificial-intelligence-native platform in an effort to speed up clinical development.

Extensive peer-reviewed research has identified biologically active nutrients and biochemical intermediates that play ...

Clay brings a distinguished track record in global project delivery and site relationship strategy. He has led large-scale ...

PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for 2026 in patients with metabolic and fibrotic diseaseCarmel Nanthakumar, ...

GREENVILLE, SC, UNITED STATES, February 11, 2026 /EINPresswire.com/ -- • ATC-002 is a topical treatment designed to ...

Core Economic Terms of $6.0 Million Financing Remain Unchanged Jupiter Neurosciences, Inc. (NASDAQ:JUNS)That alignment ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Science Exchange, the leading SaaS provider of supplier orchestration solutions for the life sciences industry, today announced the launch of its Clinical ...

Diversity in clinical trials matters for drug safety and efficacy—and for future medical advancements. Clinical trial ...

New Appointments Reinforce Operational Readiness Across Finance, Regulatory Affairs, and Program Leadership Phio ...